GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » 3-Year RORE %

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) 3-Year RORE % : -96.15% (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. GlaxoSmithKline Consumer Nigeria's 3-Year RORE % for the quarter that ended in Jun. 2023 was -96.15%.

The industry rank for GlaxoSmithKline Consumer Nigeria's 3-Year RORE % or its related term are showing as below:

NSA:GLAXOSMITH's 3-Year RORE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.585 vs NSA:GLAXOSMITH: -96.15

GlaxoSmithKline Consumer Nigeria 3-Year RORE % Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria 3-Year RORE % Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.53 10.89 -13.39 -60.34 52.73

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 50.00 51.02 52.73 -96.15

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's 3-Year RORE %

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Consumer Nigeria's 3-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's 3-Year RORE % falls into.



GlaxoSmithKline Consumer Nigeria 3-Year RORE % Calculation

GlaxoSmithKline Consumer Nigeria's 3-Year RORE % for the quarter that ended in Jun. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.5-0.25 )/( 1.69-1.95 )
=0.25/-0.26
=-96.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 3-year before.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


GlaxoSmithKline Consumer Nigeria 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines